Production & Sales

Circassia to buy US, China marketing rights to AIT’s AirNOvent

Circassia Pharmaceuticals has agreed to acquire the exclusive commercialization rights of AIT Therapeutics’ ventilator compatible nitric oxide product AirNOvent in the US and China.

BioNTech to acquire MAB Discovery’s antibody generation unit

BioNTech, a biotechnology company developing precise and individualized immunotherapies for the treatment of cancer and the prevention of infectious diseases, and MAB Discovery, a unique player in the generation and development of sophisticated and therapeutically relevant monoclonal antibodies (mAbs), have entered into a definitive agreement under which BioNTech will acquire MAB Discovery’s operational antibody generation unit.

Acrotech to buy seven hematology/oncology products from Spectrum

Aurobindo Pharma’s subsidiary Acrotech Biopharma has agreed to acquire seven FDA-approved hematology/oncology products from Spectrum Pharmaceuticals in a deal valued at around $300m.

Luye Pharma grants AstraZeneca exclusive rights to promote Xuezhikang Capsules in mainland China

Luye Pharma has announced it has entered an agreement with AstraZeneca China, the terms of which grant AstraZeneca China exclusive rights to promote Luye Pharma’s Xuezhikang Capsules in mainland China.

Puma Biotechnology, Knight Therapeutics sign license deal to commercialize NERLYNX in Canada

Puma Biotechnology has entered into an exclusive license agreement with Knight Therapeutics that grants Knight the exclusive right to commercialize NERLYNX (neratinib) in Canada.

Eusa Pharma acquires iMCD treatment Sylvant for $115m

Biopharmaceutical firm Eusa Pharma has purchased worldwide rights of Sylvant (siltuximab) from Janssen Sciences Ireland for $115m.

Takeda completes $62bn acquisition of Irish biotech firm Shire

Japan-based Takeda Pharmaceutical has completed its previously announced $62bn acquisition of Irish rare disease biotech company Shire.

Lilly to acquire Loxo Oncology for $8bn

Eli Lilly and Company (Lilly) has agreed to acquire Connecticut-based biopharmaceutical company Loxo Oncology in an all-cash deal worth $8bn.

Catalent to invest $200m in biologics business

Catalent, a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, has started a $200m capital investment to expand biologics capacity and capabilities.